Viral membrane fusion: a dance between proteins and lipids
There are at least 21 families of enveloped viruses that infect mammals, and many contain
members of high concern for global human health. All enveloped viruses have a dedicated …
members of high concern for global human health. All enveloped viruses have a dedicated …
Influence of glycosylation on the immunogenicity and antigenicity of viral immunogens
A key aspect of successful viral vaccine design is the elicitation of neutralizing antibodies
targeting viral attachment and fusion glycoproteins that embellish viral particles. This …
targeting viral attachment and fusion glycoproteins that embellish viral particles. This …
Map** glycoprotein structure reveals Flaviviridae evolutionary history
Viral glycoproteins drive membrane fusion in enveloped viruses and determine host range,
tissue tropism and pathogenesis. Despite their importance, there is a fragmentary …
tissue tropism and pathogenesis. Despite their importance, there is a fragmentary …
Induction of cross-neutralizing antibodies by a permuted hepatitis C virus glycoprotein nanoparticle vaccine candidate
Hepatitis C virus (HCV) infection affects approximately 58 million people and causes~
300,000 deaths yearly. The only target for HCV neutralizing antibodies is the highly …
300,000 deaths yearly. The only target for HCV neutralizing antibodies is the highly …
Structure of engineered hepatitis C virus E1E2 ectodomain in complex with neutralizing antibodies
MC Metcalf, BM Janus, R Yin, R Wang… - Nature …, 2023 - nature.com
Hepatitis C virus (HCV) is a major global health burden as the leading causative agent of
chronic liver disease and hepatocellular carcinoma. While the main antigenic target for HCV …
chronic liver disease and hepatocellular carcinoma. While the main antigenic target for HCV …
The hepatitis C virus envelope protein complex is a dimer of heterodimers
EH Augestad, C Holmboe Olesen, C Grønberg… - Nature, 2024 - nature.com
Fifty-eight million individuals worldwide are affected by chronic hepatitis C virus (HCV)
infection, a primary driver of liver cancer for which no vaccine is available. The HCV …
infection, a primary driver of liver cancer for which no vaccine is available. The HCV …
Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection
Individuals who clear primary hepatitis C virus (HCV) infections clear subsequent
reinfections more than 80% of the time, but the mechanisms are poorly defined. Here, we …
reinfections more than 80% of the time, but the mechanisms are poorly defined. Here, we …
Recent advances in protective vaccines against hepatitis viruses: A narrative review
Vaccination has been confirmed to be the safest and, sometimes, the only tool of defense
against threats from infectious diseases. The successful history of vaccination is evident in …
against threats from infectious diseases. The successful history of vaccination is evident in …
Hepatitis C virus chronicity and oncogenic potential: vaccine development progress
Y Haga, S Coates, R Ray - Molecular Aspects of Medicine, 2024 - Elsevier
Hepatitis C virus (HCV) infection is a major health problem worldwide. It can cause liver
cirrhosis and hepatocellular carcinoma (HCC), making it a cause of morbidity from liver …
cirrhosis and hepatocellular carcinoma (HCC), making it a cause of morbidity from liver …
Prospects for develo** an hepatitis C virus E1E2‐based nanoparticle vaccine
EA Toth, AK Andrianov… - Reviews in Medical …, 2023 - Wiley Online Library
Globally, more than 58 million people are chronically infected with Hepatitis C virus (HCV)
with 1.5 million new infections occurring each year. An effective vaccine for HCV is therefore …
with 1.5 million new infections occurring each year. An effective vaccine for HCV is therefore …